ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Anondita Medicare Limited has reinstated its previous rights issue corrigendum. The issue size is now confirmed at 9,58,166 equity shares, aggregating to ₹91.03 Crore.
Anondita Medicare Limited issued a corrigendum to its Rights Issue, revising the total issue size to ₹91.03 Crore and adjusting the allocation for general corporate purposes.
Anondita Medicare Limited has fixed September 02, 2026, as the record date for determining shareholders eligible for its Rights Issue of Equity Shares.
Anondita Medicare Limited approved a rights issue of 9,58,000 equity shares at an issue price of ₹950 per share.
Anondita Medicare Limited received in-principle approval from NSE for a proposed Rights Issue. The issue aggregates up to ₹109.78 Crore at a face value of ₹10 per share.
Anondita Medicare Ltd issued 285,000 convertible preferential shares at ₹1,038 each, raising approximately ₹29.58 Crore. The issue increased paid‑up capital to ₹183.72 Crore, with the promoter as sole investor.
Anondita Medicare allotted 2,85,000 convertible warrants at Rs.1,038 each to a promoter. The transaction totals Rs.29.58 Crore with an 18-month conversion period.
Anondita Medicare received NSE in-principle approval to issue 2.85 lakh convertible warrants at Rs. 1,038 each. The Rs. 29.58 Crore preferential issuance targets the promoter category.
Anondita Medicare Limited approved an amendment to its Memorandum of Association's main object clause. The expanded scope includes sexual wellness, personal care, and healthcare products.
Anondita Medicare Limited's Board has approved an alteration to its Memorandum of Association's Main Objects. The amendment expands its business scope from male latex contraceptives to include female condoms, sexual wellness, personal care, healthcare products, diagnostic kits, and medical gloves. This strategic shift signals a significant diversification beyond its core condom manufacturing operations.